FAM223A: A Potential Drug Target and Biomarker (G100132967)

Target Name: FAM223A

NCBI ID: G100132967

FAM223A

FAM223A: A Potential Drug Target and Biomarker

FAM223A is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern have made it an attractive target for researchers to investigate, and its potential as a drug target has led to a significant amount of research in the field.

The FAM223A gene is located on chromosome 6p21.2 and encodes a protein known as FAM223A, which is a key regulator of the microtubule network. The microtubules are a protein structure that organizes the mitotic spindle in the cell, and they play a crucial role in cell division, intracellular transport, and other cellular processes. FAM223A is known to regulate the stability of microtubules and is involved in the regulation of cell cycle progression, which is a critical step in the development and progression of many diseases.

FAM223A has been shown to be involved in various cellular processes, including cell division, cell migration, and the regulation of the cytoskeleton. It has been shown to play a role in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as in the regulation of cancer cell growth and metastasis.

FAM223A has also been shown to be involved in the regulation of pain perception and the modulation of pain signaling pathways. This makes it an attractive target for the development of pain medications. Additionally, FAM223A has been shown to be involved in the regulation of sleep and wakefulness, which makes it an attractive target for the development of wakefulness drugs.

In addition to its potential as a drug target, FAM223A has also been shown to be a potential biomarker for various diseases. The FAM223A gene has been shown to be expressed in a variety of tissues and cells, including brain, spinal cord, and muscle. Additionally, studies have shown that FAM223A is involved in the regulation of cellular processes that are important for disease development, such as neurodegeneration, cancer, and pain.

FAM223A has also been shown to be involved in the regulation of inflammation, which makes it an attractive target for the development of anti-inflammatory drugs. Additionally, FAM223A has been shown to be involved in the regulation of cellular signaling pathways, including TGF-β signaling pathways, which are involved in the regulation of cell growth and differentiation.

In conclusion, FAM223A is a gene that has the potential to be a drug target and biomarker for a variety of diseases. Its unique structure and expression pattern make it an attractive target for researchers to investigate, and its involvement in various cellular processes and its potential as a drug target and biomarker make it an attractive target for drug development. Further research is needed to fully understand the role of FAM223A in disease development and to develop effective treatments.

Protein Name: Family With Sequence Similarity 223 Member A

The "FAM223A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM223A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets